Literature DB >> 32941004

Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain.

Deepto Mozumdar1,2, Amy Doerner1, Justin Y Zhang1, Diane N Rafizadeh1, Alanna Schepartz2.   

Abstract

Mutations in the epidermal growth factor receptor (EGFR) extracellular domain (ECD) are implicated in the development of glioblastoma multiforme (GBM), which is a highly aggressive form of brain cancer. Of particular interest to GBM is the EGFR variant known as EGFRvIII, which is distinguished by an in-frame deletion of exons 2-7, which encode ECD residues 6-273. Included within the deleted region is an autoinhibitory tether, whose absence, alongside unique disulfide interactions within the truncated ECD, supports assembly of a constitutively active asymmetric kinase dimer. Previous studies have shown that the binding of growth factors to the ECD of wild-type EGFR leads to the formation of two distinct coiled coil dimers in the cytoplasmic juxtamembrane (JM) segment, whose identities correlate with the downstream phenotype. One coiled coil contains leucine residues at the interhelix interface (EGF-type), whereas the other contains charged and polar side chains (TGF-α-type). It has been proposed that growth-factor-dependent structural changes in the ECD and adjacent transmembrane helix are transduced into distinct JM coiled coils. Here, we show that, in the absence of this growth-factor-induced signal, the JM of EGFRvIII adopts both EGF-type and TGF-α-type structures, providing direct evidence for this hypothesis. These studies confirm that the signals that define JM coiled coil identity begin within the ECD, and support a model in which growth-factor-induced conformational changes are transmitted from the ECD through the transmembrane helix to favor different coiled coil isomers within the JM.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32941004      PMCID: PMC7906117          DOI: 10.1021/acs.biochem.0c00641

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  48 in total

1.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

Authors:  N Sugawa; A J Ekstrand; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.

Authors:  M Nagane; F Coufal; H Lin; O Bögler; W K Cavenee; H J Huang
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

3.  Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.

Authors:  Thomas P J Garrett; Neil M McKern; Meizhen Lou; Thomas C Elleman; Timothy E Adams; George O Lovrecz; Hong-Jian Zhu; Francesca Walker; Morry J Frenkel; Peter A Hoyne; Robert N Jorissen; Edouard C Nice; Antony W Burgess; Colin W Ward
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

4.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

Authors:  L Frederick; X Y Wang; G Eley; C D James
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

Review 5.  The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.

Authors:  Hui K Gan; Anna N Cvrljevic; Terrance G Johns
Journal:  FEBS J       Date:  2013-07-08       Impact factor: 5.542

6.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

Authors:  R Nishikawa; X D Ji; R C Harmon; C S Lazar; G N Gill; W K Cavenee; H J Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

Review 7.  The EGFRvIII variant in glioblastoma multiforme.

Authors:  Hui K Gan; Andrew H Kaye; Rodney B Luwor
Journal:  J Clin Neurosci       Date:  2009-03-25       Impact factor: 1.961

8.  Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.

Authors:  Natalia Jura; Nicholas F Endres; Kate Engel; Sebastian Deindl; Rahul Das; Meindert H Lamers; David E Wemmer; Xuewu Zhang; John Kuriyan
Journal:  Cell       Date:  2009-06-26       Impact factor: 41.582

9.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397

10.  Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Authors:  Yong Jia; Cai-Hong Yun; Eunyoung Park; Dalia Ercan; Mari Manuia; Jose Juarez; Chunxiao Xu; Kevin Rhee; Ting Chen; Haikuo Zhang; Sangeetha Palakurthi; Jaebong Jang; Gerald Lelais; Michael DiDonato; Badry Bursulaya; Pierre-Yves Michellys; Robert Epple; Thomas H Marsilje; Matthew McNeill; Wenshuo Lu; Jennifer Harris; Steven Bender; Kwok-Kin Wong; Pasi A Jänne; Michael J Eck
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.